CanAssist Breast is a prognostic test that can help guide treatment decisions in your cancer journey. By delving deep into the molecular-level architecture of a patient's tumor, the test provides clinicians with valuable information that can help them design appropriate treatment regimens. Here's how it works: CanAssist Breast evaluates multiple biomarkers in the tumor tissue sample to calculate a ‘risk score’ using a unique AI-driven algorithm. This score helps predict the likelihood of distant cancer recurrence within five years after surgery, allowing physicians to tailor treatment strategies based on individual risk.

What is the benefit of this approach? It avoids over-treatment in low-risk patients, reducing unnecessary side effects from extreme medication, as well as the associated healthcare costs. At the same time, the test ensures that aggressive therapies are initiated at the right time for high-risk patients. CanAssist Breast, therefore, represents a significant step forward in personalized breast cancer care, empowering patients and clinicians with the insights they need to make informed treatment decisions. It's all about treating the right patient at the right time.